RAB17

Across TCGA pan-cancer cohorts, RAB17 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RAB17 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher RAB17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAB17 expression acts as an unfavorable survival marker.

DLBC are the cancer types where RAB17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

RAB17–DLBC (OS)

Open the DLBC breakdown →